Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Evaluation of the Prophylactic Effect of Hydroxychloroquine on People in Close-Contact with Patients with Covid-19

Shabani et al., Pulmonary Pharmacology & Therapeutics, doi:10.1016/j.pupt.2021.102069
Aug 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Symp. case 19% Improvement Relative Risk Case -6% Case (b) -22% HCQ for COVID-19  Shabani et al.  Prophylaxis Is post-exposure prophylaxis with HCQ beneficial for COVID-19? Prospective study of 113 patients in Iran Study underpowered to detect differences c19hcq.org Shabani et al., Pulmonary Pharmacology.., Aug 2021 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
Small PEP trial with 51 HCQ patients, not showing a significant difference in cases. IRCT20130917014693N10.
risk of symptomatic case, 19.0% lower, RR 0.81, p = 1.00, treatment 2 of 51 (3.9%), control 3 of 62 (4.8%), NNT 109, day 7.
risk of case, 6.4% higher, RR 1.06, p = 1.00, treatment 7 of 51 (13.7%), control 8 of 62 (12.9%), day 7, PCR+ and symptomatic.
risk of case, 21.6% higher, RR 1.22, p = 0.78, treatment 7 of 51 (13.7%), control 7 of 62 (11.3%), day 7, PCR+ only.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shabani et al., 10 Aug 2021, prospective, Iran, peer-reviewed, 16 authors.
This PaperHCQAll
Evaluation of the prophylactic effect of hydroxychloroquine on people in close-contact with patients with COVID-19
Minoosh Shabani, Mehdi Totonchi, Omidvar Rezaeimirghaed, Latif Gachkar, Mohammadreza Hajiesmaeili, Ali Khoshkar, Mahdi Amirdosara, Ali Saffaei, Shervin Shokouhi, Masoud Mardani, Ilad Alavi Darazam, Alireza Karami, Milad Sharifi, Mana Zaman, Elham Abedheydari, Dr Zahra Sahraei
Pulmonary Pharmacology & Therapeutics, doi:10.1016/j.pupt.2021.102069
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
Al-Bari, Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases, Pharmacol Res Perspect
Boulware, Matthew, Pullen, Ananta, Bangdiwala et al., -p r o o f
Chatterjee, Nagi, Agarwal, Das, Banerjee et al., The 2019 novel coronavirus disease (COVID-19) pandemic: A review of the current evidence, Indian J Med Res
Fisher, Tenforde, Feldstein, Lindsell, Shapiro et al., IVY Network Investigators; CDC COVID-19 Response Team. Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities -United States, MMWR Morb Mortal Wkly Rep
Guo, Cao, Hong, Tan, Chen et al., The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status, Mil Med Res
Kelly, Ilan, Schwartz, Ph, Emily et al., A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19, N Engl J Med
Lake, What we know so far: COVID-19 current clinical knowledge and research, Clinical medicine
Marovich, Mascola, Cohen, Monoclonal Antibodies for Prevention and Treatment of COVID-19, JAMA
Melles, Zhang, Lu, Rai, Young, Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines, Arthritis Res Ther, doi:10.1186/s13075-018-1634-8
Prasad Dhibar, Arora, Kakkar, Singla, Mohindra et al., Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study, Int J Antimicrob Agents
Principi, Esposito, Chloroquine or hydroxychloroquine for prophylaxis of COVID-19, Lancet Infect Dis, doi:10.1016/S1473-3099(20)30296-6
Rainsford, Parke, Clifford-Rashotte, Kean, Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases, Inflammopharmacology
Rajasingham, Ananta, Bangdiwala, Nicol, Skipper et al., Hydroxychloroquine as preexposure prophylaxis for COVID-19 in healthcare workers: a randomized trial
Shabani Barzegar ; Zhou, Yang, Wang, Hu, Zhang et al., Conceptualization, Methodology, Investigation, Data Curation, Writing -Original Draft, Writing -Review & Editing, Project administration Mehdi Totonchi: Conceptualization, Data Curation, Formal analysis Writing -Review & Editing Omidvar Rezaeimirghaed: Conceptualization, Data Curation, Writing -Review & Editing Latif Gachkar: Conceptualization, Data Curation, Writing -Review & Editing Mohammadreza Hajiesmaeili: Conceptualization, Data Curation, Writing -Review & Editing Ali Khoshkar: Conceptualization, Data Curation, Writing -Review & Editing Mahdi Amirdosara: Conceptualization, Data Curation, Writing -Review & Editing Ali Saffaei: Conceptualization, Data Curation, Formal analysis, Writing -Review & Editing Shervin Shokouhi: Conceptualization, Data Curation, Writing -Review & Editing Masoud Mardani: Conceptualization, Data Curation, Writing -Review & Editing Ilad Alavi Darazam: Conceptualization, Data Curation, Writing
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Yao, Ye, Zhang, Cui, Huang et al., Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clinical Infectious Diseases
{ 'indexed': {'date-parts': [[2024, 2, 2]], 'date-time': '2024-02-02T06:38:44Z', 'timestamp': 1706855924705}, 'reference-count': 16, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2021, 10, 1]], 'date-time': '2021-10-01T00:00:00Z', 'timestamp': 1633046400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2021, 10, 1]], 'date-time': '2021-10-01T00:00:00Z', 'timestamp': 1633046400000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-017'}, { 'start': { 'date-parts': [[2021, 10, 1]], 'date-time': '2021-10-01T00:00:00Z', 'timestamp': 1633046400000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-037'}, { 'start': { 'date-parts': [[2021, 10, 1]], 'date-time': '2021-10-01T00:00:00Z', 'timestamp': 1633046400000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-012'}, { 'start': { 'date-parts': [[2021, 10, 1]], 'date-time': '2021-10-01T00:00:00Z', 'timestamp': 1633046400000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-029'}, { 'start': { 'date-parts': [[2021, 10, 1]], 'date-time': '2021-10-01T00:00:00Z', 'timestamp': 1633046400000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-004'}], 'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au', 'clinicalkey.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021, 10]]}, 'DOI': '10.1016/j.pupt.2021.102069', 'type': 'journal-article', 'created': {'date-parts': [[2021, 8, 10]], 'date-time': '2021-08-10T17:01:16Z', 'timestamp': 1628614876000}, 'page': '102069', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 4, 'title': 'Evaluation of the prophylactic effect of hydroxychloroquine on people in close-contact with ' 'patients with COVID-19', 'prefix': '10.1016', 'volume': '70', 'author': [ {'given': 'Minoosh', 'family': 'Shabani', 'sequence': 'first', 'affiliation': []}, {'given': 'Mehdi', 'family': 'Totonchi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Omidvar', 'family': 'Rezaeimirghaed', 'sequence': 'additional', 'affiliation': []}, {'given': 'Latif', 'family': 'Gachkar', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Mohammadreza', 'family': 'Hajiesmaeili', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ali', 'family': 'Khoshkar', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mahdi', 'family': 'Amirdosara', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ali', 'family': 'Saffaei', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shervin', 'family': 'Shokouhi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Masoud', 'family': 'Mardani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ilad', 'family': 'Alavi Darazam', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-7853-7006', 'authenticated-orcid': False, 'given': 'Alireza', 'family': 'Karami', 'sequence': 'additional', 'affiliation': []}, {'given': 'Milad', 'family': 'Sharifi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mana', 'family': 'Zaman', 'sequence': 'additional', 'affiliation': []}, {'given': 'Elham', 'family': 'Abedheydari', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zahra', 'family': 'Sahraei', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.pupt.2021.102069_bib1', 'doi-asserted-by': 'crossref', 'first-page': '270', 'DOI': '10.1038/s41586-020-2012-7', 'article-title': 'A pneumonia outbreak associated with a new coronavirus of probable bat ' 'origin', 'volume': '579', 'author': 'Zhou', 'year': '2020', 'journal-title': 'Nature'}, { 'issue': '2,3', 'key': '10.1016/j.pupt.2021.102069_bib2', 'article-title': 'The 2019 novel coronavirus disease (COVID-19) pandemic: a review of the ' 'current evidence', 'volume': '151', 'author': 'Chatterjee', 'year': '2020', 'journal-title': 'Indian J. Med. Res.'}, { 'key': '10.1016/j.pupt.2021.102069_bib3', 'doi-asserted-by': 'crossref', 'first-page': '124', 'DOI': '10.7861/clinmed.2019-coron', 'article-title': 'What we know so far: COVID-19 current clinical knowledge and research', 'volume': '20', 'author': 'Lake', 'year': '2020', 'journal-title': 'Clin. Med.'}, { 'key': '10.1016/j.pupt.2021.102069_bib4', 'first-page': '11', 'article-title': 'The origin, transmission and clinical therapies on coronavirus disease ' '2019 (COVID-19) outbreak - an update on the status', 'volume': '7', 'author': 'Guo', 'year': '2020', 'journal-title': 'Mil. Med. Res.'}, { 'issue': '2', 'key': '10.1016/j.pupt.2021.102069_bib5', 'doi-asserted-by': 'crossref', 'first-page': '131', 'DOI': '10.1001/jama.2020.10245', 'article-title': 'Monoclonal antibodies for prevention and treatment of COVID-19', 'volume': '324', 'author': 'Marovich', 'year': '2020', 'journal-title': 'J. Am. Med. Assoc.'}, { 'key': '10.1016/j.pupt.2021.102069_bib6', 'doi-asserted-by': 'crossref', 'first-page': '269', 'DOI': '10.1038/s41422-020-0282-0', 'article-title': 'Remdesivir and chloroquine effectively inhibit the recently emerged ' 'novel coronavirus (2019-nCoV) in vitro', 'volume': '30', 'author': 'Wang', 'year': '2020', 'journal-title': 'Cell Res.'}, { 'key': '10.1016/j.pupt.2021.102069_bib7', 'doi-asserted-by': 'crossref', 'DOI': '10.1002/prp2.293', 'article-title': 'Targeting endosomal acidification by chloroquine analogs as a promising ' 'strategy for the treatment of emerging viral diseases', 'volume': '5', 'author': 'Al-Bari', 'year': '2017', 'journal-title': 'Pharmacol. Res. Perspect.'}, { 'key': '10.1016/j.pupt.2021.102069_bib8', 'article-title': 'Remdesivir and chloroquine effectively inhibit the recently emerged ' 'novel coronavirus (2019-nCoV) in vitro', 'author': 'Wang', 'year': '2020', 'journal-title': 'Cell Res.'}, { 'issue': '5', 'key': '10.1016/j.pupt.2021.102069_bib9', 'doi-asserted-by': 'crossref', 'first-page': '231', 'DOI': '10.1007/s10787-015-0239-y', 'article-title': 'Therapy and pharmacological properties of hydroxychloroquine and ' 'chloroquine in treatment of systemic lupus erythematosus, rheumatoid ' 'arthritis and related diseases', 'volume': '23', 'author': 'Rainsford', 'year': '2015', 'journal-title': 'Inflammopharmacology'}, { 'key': '10.1016/j.pupt.2021.102069_bib10', 'doi-asserted-by': 'crossref', 'first-page': '133', 'DOI': '10.1186/s13075-018-1634-8', 'article-title': 'Hydroxychloroquine prescription trends and predictors for excess dosing ' 'per recent ophthalmology guidelines', 'volume': '20', 'author': 'Jorge', 'year': '2018', 'journal-title': 'Arthritis Res. Ther.'}, { 'issue': '36', 'key': '10.1016/j.pupt.2021.102069_bib11', 'doi-asserted-by': 'crossref', 'first-page': '1258', 'DOI': '10.15585/mmwr.mm6936a5', 'article-title': 'Community and close contact exposures associated with COVID-19 among ' 'symptomatic adults ≥18 Years in 11 outpatient health care facilities - ' 'United States, July 2020', 'volume': '69', 'author': 'Fisher', 'year': '2020', 'journal-title': 'MMWR Morb. Mortal. Wkly. Rep.'}, { 'key': '10.1016/j.pupt.2021.102069_bib12', 'doi-asserted-by': 'crossref', 'DOI': '10.1056/NEJMoa2016638', 'article-title': 'A randomized trial of hydroxychloroquine as postexposure prophylaxis ' 'for Covid-19', 'author': 'Boulware', 'year': '2020', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '10.1016/j.pupt.2021.102069_bib13', 'doi-asserted-by': 'crossref', 'first-page': '732', 'DOI': '10.1093/cid/ciaa237', 'article-title': 'In vitro antiviral activity and projection of optimized dosing design ' 'of hydroxychloroquine for the treatment of severe acute respiratory ' 'syndrome coronavirus 2 (SARS-CoV-2)', 'volume': '71', 'author': 'Yao', 'year': '2020', 'journal-title': 'Clin. Infect. Dis.'}, { 'issue': '10', 'key': '10.1016/j.pupt.2021.102069_bib14', 'doi-asserted-by': 'crossref', 'first-page': '1118', 'DOI': '10.1016/S1473-3099(20)30296-6', 'article-title': 'Chloroquine or hydroxychloroquine for prophylaxis of COVID-19', 'volume': '20', 'author': 'Principi', 'year': '2020', 'journal-title': 'Lancet Infect. Dis.'}, { 'issue': '6', 'key': '10.1016/j.pupt.2021.102069_bib15', 'doi-asserted-by': 'crossref', 'first-page': '106224', 'DOI': '10.1016/j.ijantimicag.2020.106224', 'article-title': 'Post-exposure prophylaxis with hydroxychloroquine for the prevention of ' 'COVID-19, a myth or a reality? The PEP-CQ Study', 'volume': '56', 'author': 'Prasad Dhibar', 'year': '2020', 'journal-title': 'Int. J. Antimicrob. Agents'}, { 'key': '10.1016/j.pupt.2021.102069_bib16', 'series-title': 'Hydroxychloroquine as Pre-exposure Prophylaxis for COVID-19 in ' 'Healthcare Workers: a Randomized Trial, Version 1. medRxiv', 'author': 'Rajasingham', 'year': '2020'}], 'container-title': 'Pulmonary Pharmacology &amp; Therapeutics', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S109455392100081X?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S109455392100081X?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2023, 3, 27]], 'date-time': '2023-03-27T23:24:29Z', 'timestamp': 1679959469000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S109455392100081X'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 10]]}, 'references-count': 16, 'alternative-id': ['S109455392100081X'], 'URL': 'http://dx.doi.org/10.1016/j.pupt.2021.102069', 'relation': {}, 'ISSN': ['1094-5539'], 'subject': ['Pharmacology (medical)', 'Biochemistry (medical)', 'Pulmonary and Respiratory Medicine'], 'container-title-short': 'Pulmonary Pharmacology &amp; Therapeutics', 'published': {'date-parts': [[2021, 10]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Evaluation of the prophylactic effect of hydroxychloroquine on people in ' 'close-contact with patients with COVID-19', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'Pulmonary Pharmacology & Therapeutics', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.pupt.2021.102069', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2021 Elsevier Ltd. All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '102069'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit